Whilst this clearly shows the antitumour potency of combining BiTEs and CPIs, safety must be a concern given the expression of HER2 on healthy tissues such as the heart and lungs [18], and a case report of fatal CRS during a study of CAR-T therapy targeted against HER2 [19]. Here, ERBB2 is linked to congenital rubella syndrome.